Ramasastry Saira 4

What Happened
Director Saira Ramasastry was granted a derivative award covering 25,000 shares of Sensei Biotherapeutics (FTH) on June 12, 2026. The award shows a $0.00 acquisition price (no immediate cash outlay reported). This is an award/grant (code A) rather than an open-market purchase or sale.

Key Details

• Transaction date: June 12, 2026; filing date: June 16, 2026 (timely filing).
• Instrument: Derivative award/grant covering 25,000 shares; reported acquisition price $0.00.
• Vesting: 36 equal monthly installments over three years; fully vested on June 12, 2029, contingent on continuous service (per footnote).
• Shares owned after the transaction: Not specified in the filing.
• Filing status: Timely (filed within required reporting window). No 10b5-1 plan, tax-withholding, or sale reported in this filing.

Context
This was a compensation award to a director rather than a market purchase or sale. Such grants are commonly used for director compensation and become economically meaningful only as they vest (or are exercised/settled) and any associated taxes are handled. The filing does not indicate any immediate sale or exercise of underlying shares.